ITGB2 / LFA-1 Immunizing Peptide
Référence MBS428532-0,1mg
Conditionnement : 0.1mg
Marque : MyBiosource
ITGB2 / LFA-1 Immunizing Blocking Peptide
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS428532MBS428532 is a blocking peptide targeting ITGB2. Also known as ITGB2 / LFA-1 Immunizing Peptide. Reactive in Human. More details
Product Overview
Product Name
ITGB2 / LFA-1, Blocking Peptide
Full Product Name
ITGB2 / LFA-1 Immunizing Peptide
Product Gene Name
ITGB2 blocking peptide
Product Synonym Gene Name
LFA-1
Product Synonym Names
ITGB2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); CD18; LAD; LCAMB; LFA-1; MAC-1; MF17; MFI7; cell surface adhesion glycoprotein LFA-1/CR3/P150,959 beta subunit precursor); cell surface adhesion glycoproteins LFA-1/CR3/p150,95 sub; ITGB2 / LFA-1 (aa86-99)
Sequence
C-ETQEDHNG GQKQLS
Species Reactivity
Human
Form/Format
100µg of Lyophilised peptide, formulation De-ionized (DI) water.Reconstitute pellet in distilled water where required. For Blocking studies, reconstitutepellet in 200µl distilled water to obtain a 0.5mg/ml peptide solution.
Preparation and Storage
Shipped at ambient temperature, store at -20°C
Antibody/Peptide Pairs
ITGB2 / LFA-1 peptide (MBS428532) is used for blocking the activity of ITGB2/LFA-1 antibody (MBS423409)
OMIM
116920
ISO Certification
Manufactured in an ISO 9001:2008 Certified Laboratory.
Other Notes
Small volumes of ITGB2 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for ITGB2. It may not necessarily be applicable to this product.
NCBI Official Full Name
integrin beta-2
NCBI Official Synonym Full Names
integrin subunit beta 2
NCBI Official Symbol
ITGB2
NCBI Official Synonym Symbols
LAD; CD18; MF17; MFI7; LCAMB; LFA-1; MAC-1
UniProt Protein Name
Integrin beta-2
UniProt Synonym Protein Names
Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; Complement receptor C3 subunit beta; CD_antigen: CD18
Protein Family
Integrin
UniProt Gene Name
ITGB2
UniProt Synonym Gene Names
CD18; MFI7
UniProt Entry Name
ITB2_HUMAN
NCBI Protein Information
integrin beta-2
NCBI Summary for ITGB2
This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers. Integrins are integral cell-surface proteins that participate in cell adhesion as well as cell-surface mediated signalling. The encoded protein plays an important role in immune response and defects in this gene cause leukocyte adhesion deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]
Show more UniProt Comments for ITGB2
ITGB2: the integrin beta 2 subunit. Can combine with multiple partners resulting in different integrins. For example, beta 2 combines with the alpha L chain to form the integrin LFA-1, and combines with the alpha M chain to form the integrin Mac-1. Participates in cell adhesion as well as cell-surface mediated signaling. Defects are the cause of leukocyte adhesion deficiency type I (LAD1).
Protein type: Membrane protein, integral; Cell adhesion; Motility/polarity/chemotaxis; Receptor, misc.; Cell surface
Chromosomal Location of Human Ortholog: 21q22.3
Cellular Component: cell surface; integrin complex; membrane; plasma membrane; receptor complex; secretory granule
Molecular Function: cell adhesion molecule binding; glycoprotein binding; ICAM-3 receptor activity; metal ion binding; protein binding; protein complex binding; protein heterodimerization activity; protein kinase binding
Biological Process: activation of NF-kappaB transcription factor; aging; apoptosis; cell adhesion; cell-cell signaling; cell-matrix adhesion; cellular extravasation; endothelial cell migration; extracellular matrix organization and biogenesis; heterotypic cell-cell adhesion; inflammatory response; integrin-mediated signaling pathway; leukocyte adhesion; leukocyte migration; leukocyte migration during inflammatory response; natural killer cell activation; neutrophil chemotaxis; positive regulation of angiogenesis; positive regulation of nitric oxide biosynthetic process; receptor clustering; receptor internalization; regulation of cell shape; regulation of immune response; regulation of peptidyl-tyrosine phosphorylation; toll-like receptor 4 signaling pathway
Disease: Leukocyte Adhesion Deficiency, Type I
Show more Protein type: Membrane protein, integral; Cell adhesion; Motility/polarity/chemotaxis; Receptor, misc.; Cell surface
Chromosomal Location of Human Ortholog: 21q22.3
Cellular Component: cell surface; integrin complex; membrane; plasma membrane; receptor complex; secretory granule
Molecular Function: cell adhesion molecule binding; glycoprotein binding; ICAM-3 receptor activity; metal ion binding; protein binding; protein complex binding; protein heterodimerization activity; protein kinase binding
Biological Process: activation of NF-kappaB transcription factor; aging; apoptosis; cell adhesion; cell-cell signaling; cell-matrix adhesion; cellular extravasation; endothelial cell migration; extracellular matrix organization and biogenesis; heterotypic cell-cell adhesion; inflammatory response; integrin-mediated signaling pathway; leukocyte adhesion; leukocyte migration; leukocyte migration during inflammatory response; natural killer cell activation; neutrophil chemotaxis; positive regulation of angiogenesis; positive regulation of nitric oxide biosynthetic process; receptor clustering; receptor internalization; regulation of cell shape; regulation of immune response; regulation of peptidyl-tyrosine phosphorylation; toll-like receptor 4 signaling pathway
Disease: Leukocyte Adhesion Deficiency, Type I
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with ITGB2 blocking peptide
| Reference Product | PubMed Publications |
|---|---|
| ITGAL blocking peptide | >12 publications with ITGB2 and ITGAL |
| ICAM1 blocking peptide | >7 publications with ITGB2 and ICAM1 |
| ITGAM blocking peptide | >6 publications with ITGB2 and ITGAM |
| ITGAX blocking peptide | >4 publications with ITGB2 and ITGAX |
| ITGA5 blocking peptide | >2 publications with ITGB2 and ITGA5 |
| ITGA8 blocking peptide | >1 publications with ITGB2 and ITGA8 |
| ITGAD blocking peptide | >1 publications with ITGB2 and ITGAD |
Pathways associated with ITGB2 blocking peptide
| Products by Pathway | Pathway Diagram |
|---|---|
| Adaptive Immune System Pathway antibodies | Adaptive Immune System Pathway Diagram |
| Amoebiasis Pathway antibodies | Amoebiasis Pathway Diagram |
| Amoebiasis Pathway antibodies | Amoebiasis Pathway Diagram |
| CXCR3-mediated Signaling Events Pathway antibodies | CXCR3-mediated Signaling Events Pathway Diagram |
| Cell Adhesion Molecules (CAMs) Pathway antibodies | Cell Adhesion Molecules (CAMs) Pathway Diagram |
| Cell Adhesion Molecules (CAMs) Pathway antibodies | Cell Adhesion Molecules (CAMs) Pathway Diagram |
| Cell Surface Interactions At The Vascular Wall Pathway antibodies | Cell Surface Interactions At The Vascular Wall Pathway Diagram |
| Complement And Coagulation Cascades Pathway antibodies | Complement And Coagulation Cascades Pathway Diagram |
| Complement And Coagulation Cascades Pathway antibodies | Complement And Coagulation Cascades Pathway Diagram |
| Extracellular Matrix Organization Pathway antibodies | Extracellular Matrix Organization Pathway Diagram |
Diseases associated with ITGB2 blocking peptide
| Disease Name | Pubmed Publications |
|---|---|
| Inflammation Antibodies | >958 publications with ITGB2 and Inflammation |
| Necrosis Antibodies | >627 publications with ITGB2 and Necrosis |
| Cardiovascular Diseases Antibodies | >417 publications with ITGB2 and Cardiovascular Diseases |
| Lung Diseases Antibodies | >222 publications with ITGB2 and Lung Diseases |
| Leukocyte-Adhesion Deficiency Syndrome Antibodies | >175 publications with ITGB2 and Leukocyte-Adhesion Deficiency Syndrome |
| Heart Diseases Antibodies | >132 publications with ITGB2 and Heart Diseases |
| Leukocyte Disorders Antibodies | >122 publications with ITGB2 and Leukocyte Disorders |
| Hypersensitivity Antibodies | >117 publications with ITGB2 and Hypersensitivity |
| Atherosclerosis Antibodies | >81 publications with ITGB2 and Atherosclerosis |
| Kidney Diseases Antibodies | >72 publications with ITGB2 and Kidney Diseases |
Organs/Tissues associated with ITGB2 blocking peptide
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >3808 publications with ITGB2 and Blood |
| Lung Antibodies | >380 publications with ITGB2 and Lung |
| Bone Antibodies | >298 publications with ITGB2 and Bone |
| Bone Marrow Antibodies | >268 publications with ITGB2 and Bone Marrow |
| Heart Antibodies | >191 publications with ITGB2 and Heart |
| Muscle Antibodies | >169 publications with ITGB2 and Muscle |
| Liver Antibodies | >129 publications with ITGB2 and Liver |
| Embryonic Tissue Antibodies | >124 publications with ITGB2 and Embryonic Tissue |
| Brain Antibodies | >111 publications with ITGB2 and Brain |
| Kidney Antibodies | >109 publications with ITGB2 and Kidney |
Vous serez peut-être également intéressé par les produits suivants :
Référence
Description
Cond.
Prix HT